Bausch Health Companies (BHC) PT Raised to $30 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 2/1/2023
- Wall St gains over 1% after encouraging inflation data with Fed next
- Snap shares plunge 14% following Q4 report, warns of sales drop
- ExxonMobil gains following record profit, 'solid execution'
- AMD shares rise after Q4 report that beat expectations for revenue, EPS
- Match (MTCH) slumps on Q4 miss and lower guidance
- Upstart Holdings (UPST) to lay off 20% of workforce due to current macro headwinds
- General Motors (GM) Invests $650M in Lithium Americas (LAC), Enters Supply Agreement
- HubSpot (HUBS) plans reduction of workforce by approximately 7%
- Context's (CNTX) Partner Stemline Therapeutics Announces FDA Approval of ORSERDU
- NetApp (NTAP) sees charges from plan to restructure
- After-hours movers: Snap and Match sinks on weak outlooks, AMD gains on EPS
- Midday movers: General Motors, McDonald's, Pfizer and more
- Pfizer, McDonald's fall in premarket, International Paper, UPS jump
- After-hours movers: NXP falls following results, Whirlpool gains
- Exxon Mobil, Pfizer, McDonald's earnings: 3 things to watch
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
August 7, 2018 7:00 AM EDTLAVAL, Quebec, Aug. 7, 2018 /PRNewswire/ --
Second-Quarter 2018 Financial Results Revenues of $2.128 Billion GAAP Net Loss of $873 Million GAAP Cash Flow from Operations of $222 Million Adjusted EBITDA (non-GAAP)1 of $868 Million Delivered Second Consecutive Quarter of Overall Organic Revenue Growth2, Driven by the Salix and Bausch + Lomb/International Segments3 XIFAXAN® Revenue Increased by 26% Compared to the Second Quarter of 2017 Maintained Revenue Guidance Range and Raised Full-Year Adjusted EBITDA (non-GAAP) Guidance RangeBausch Health Companies... More
